IBDEI14P ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18851,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,18851,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,18852,0)
 ;;=R59.9^^94^916^60
 ;;^UTILITY(U,$J,358.3,18852,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18852,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,18852,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,18852,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,18853,0)
 ;;=D47.3^^94^916^61
 ;;^UTILITY(U,$J,358.3,18853,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18853,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,18853,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,18853,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,18854,0)
 ;;=C82.09^^94^916^62
 ;;^UTILITY(U,$J,358.3,18854,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18854,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18854,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,18854,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,18855,0)
 ;;=C82.00^^94^916^63
 ;;^UTILITY(U,$J,358.3,18855,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18855,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,18855,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,18855,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,18856,0)
 ;;=C82.19^^94^916^64
 ;;^UTILITY(U,$J,358.3,18856,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18856,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18856,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,18856,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,18857,0)
 ;;=C82.10^^94^916^65
 ;;^UTILITY(U,$J,358.3,18857,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18857,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,18857,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,18857,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,18858,0)
 ;;=C82.29^^94^916^66
 ;;^UTILITY(U,$J,358.3,18858,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18858,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18858,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,18858,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,18859,0)
 ;;=C82.20^^94^916^67
 ;;^UTILITY(U,$J,358.3,18859,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18859,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,18859,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,18859,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,18860,0)
 ;;=C82.39^^94^916^68
 ;;^UTILITY(U,$J,358.3,18860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18860,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18860,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,18860,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,18861,0)
 ;;=C82.30^^94^916^69
 ;;^UTILITY(U,$J,358.3,18861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18861,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,18861,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,18861,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,18862,0)
 ;;=C82.49^^94^916^70
 ;;^UTILITY(U,$J,358.3,18862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18862,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18862,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,18862,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,18863,0)
 ;;=C82.40^^94^916^71
 ;;^UTILITY(U,$J,358.3,18863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18863,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,18863,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,18863,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,18864,0)
 ;;=C82.99^^94^916^72
